Siemens Healthineers

Testing firms are (again) back in favour

08/09/21 -"With the rise in Delta variant cases/risks in different parts of the world – especially in the US and Europe, testing firms are likely to witness re-emerging tailwinds. This has already begun ..."

PDF page sample
Pages
70
Language
English
Published on
08/09/21
Download
You may also be interested by these reports :
05/12/25
We have incorporated the actual figures for the FY24/25 ending in June 2025. While the recurring EBIT was in line with our forecast (€44.2m vs ...
03/12/25
Despite challenges that have reduced our target price, Demant still presents a significant upside. The company is poised to benefit from: 1) new ...
27/11/25
We have lowered our target price to reflect the business challenges outlined in the EPS section. Additionally, we have adjusted the peer-based ...
26/11/25
While Q2 sales slightly missed market expectations, Elekta’s Q2 profitability surpassed forecasts, despite tariff impacts and FX headwinds. Improved ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO